GSK Spends Heavily On iTeos' TIGIT To Build A New IO Cornerstone
Executive Summary
GSK will pay iTeos $625m up front to codevelop and cocommercialize EOS-448, now in Phase I development for advanced solid tumors.
You may also be interested in...
GSK Exits $4.2bn Cancer Drug Deal With Merck KGaA After Multiple Failures
Bintrafusp alfa was once seen as a blockbuster contender by the partners but GSK’s withdrawal narrows further its chances of success.
Roche Gives The Stage To A New Generation Of Cancer Drugs
With big oncology losses largely in the rearview mirror, Roche is trying to sell investors on its next wave of cancer drugs; R&D overview pushes message of pipeline renewal.
Despite A Third Failure, Merck KGaA And GSK Won’t Give Up On Bintrafusp Yet
After three failures in quick succession, Merck needs to see a win in one of its many remaining Phase II trials.